IL131025A0 - Treatment of autoimmune disease using tolerization in combination with methotrexate - Google Patents

Treatment of autoimmune disease using tolerization in combination with methotrexate

Info

Publication number
IL131025A0
IL131025A0 IL13102598A IL13102598A IL131025A0 IL 131025 A0 IL131025 A0 IL 131025A0 IL 13102598 A IL13102598 A IL 13102598A IL 13102598 A IL13102598 A IL 13102598A IL 131025 A0 IL131025 A0 IL 131025A0
Authority
IL
Israel
Prior art keywords
tolerization
methotrexate
treatment
combination
autoimmune disease
Prior art date
Application number
IL13102598A
Other languages
English (en)
Original Assignee
Autoimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autoimmune Inc filed Critical Autoimmune Inc
Publication of IL131025A0 publication Critical patent/IL131025A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
    • B41J—TYPEWRITERS; SELECTIVE PRINTING MECHANISMS, i.e. MECHANISMS PRINTING OTHERWISE THAN FROM A FORME; CORRECTION OF TYPOGRAPHICAL ERRORS
    • B41J2/00—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed
    • B41J2/005—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed characterised by bringing liquid or particles selectively into contact with a printing material
    • B41J2/01—Ink jet
    • B41J2/21—Ink jet for multi-colour printing
    • B41J2/2107—Ink jet for multi-colour printing characterised by the ink properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
    • G06K2215/00—Arrangements for producing a permanent visual presentation of the output data
    • G06K2215/0082—Architecture adapted for a particular function
    • G06K2215/0094—Colour printing
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
    • G06K2215/00—Arrangements for producing a permanent visual presentation of the output data
    • G06K2215/0082—Architecture adapted for a particular function
    • G06K2215/0097—Printing on special media, e.g. labels, envelopes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL13102598A 1997-01-24 1998-01-26 Treatment of autoimmune disease using tolerization in combination with methotrexate IL131025A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3672297P 1997-01-24 1997-01-24
PCT/US1998/001648 WO1998032451A1 (fr) 1997-01-24 1998-01-26 Traitement des maladies auto-immunes a l'aide d'une tolerance induite en combinaison avec du methotrexate

Publications (1)

Publication Number Publication Date
IL131025A0 true IL131025A0 (en) 2001-01-28

Family

ID=21890248

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13102598A IL131025A0 (en) 1997-01-24 1998-01-26 Treatment of autoimmune disease using tolerization in combination with methotrexate

Country Status (10)

Country Link
EP (1) EP0994717A4 (fr)
JP (1) JP2001511134A (fr)
KR (1) KR20000070460A (fr)
AU (1) AU6648898A (fr)
BR (1) BR9807112A (fr)
CA (1) CA2278152A1 (fr)
HU (1) HUP0001960A2 (fr)
IL (1) IL131025A0 (fr)
NO (1) NO993600L (fr)
WO (1) WO1998032451A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3993169B2 (ja) 2002-02-11 2007-10-17 アンタレス・ファーマ・インコーポレーテッド 皮内注射器
KR20070117543A (ko) 2005-01-24 2007-12-12 앤태어스 파머, 인코퍼레이티드 프리필 니들 조력 제트 주사기
GB0523576D0 (en) * 2005-11-18 2005-12-28 Theradeas Ltd Drug composition and its use in therapy
WO2007131013A1 (fr) 2006-05-03 2007-11-15 Antares Pharma, Inc. Injecteur de reconstitution à deux étages
US9144648B2 (en) 2006-05-03 2015-09-29 Antares Pharma, Inc. Injector with adjustable dosing
WO2009114542A1 (fr) 2008-03-10 2009-09-17 Antares Pharma, Inc. Dispositif de sécurité pour injecteur
WO2010017285A2 (fr) 2008-08-05 2010-02-11 Antares Pharma, Inc. Injecteur à dosage multiple
KR101597672B1 (ko) 2009-03-20 2016-02-25 앤태어스 파머, 인코퍼레이티드 위험 약제 주사 장치
KR20130050952A (ko) 2010-06-16 2013-05-16 브루스 챈들러 메이 인플루엔자, 감기 및 염증의 치료에서 레보세티리진 및 몬테루카스트의 용도
US9220660B2 (en) 2011-07-15 2015-12-29 Antares Pharma, Inc. Liquid-transfer adapter beveled spike
US8496619B2 (en) 2011-07-15 2013-07-30 Antares Pharma, Inc. Injection device with cammed ram assembly
WO2013134244A2 (fr) 2012-03-06 2013-09-12 Antares Pharma, Inc. Ampoule-seringue à caractéristique de force de rupture
US9950125B2 (en) 2012-04-06 2018-04-24 Antares Pharma, Inc. Needle assisted jet injection administration of testosterone compositions
WO2013169804A1 (fr) 2012-05-07 2013-11-14 Antares Pharma, Inc. Dispositif d'injection par jet assisté par une aiguille, présentant une force de déclenchement réduite
EP4349383A3 (fr) 2013-02-11 2024-06-19 Antares Pharma, Inc. Dispositif d'injection par jet assisté par aiguille ayant une force de déclenchement réduite
WO2014164786A1 (fr) 2013-03-11 2014-10-09 Madsen Patrick Injecteur de dose avec système à pignon
WO2014165136A1 (fr) 2013-03-12 2014-10-09 Antares Pharma, Inc. Seringues pré-remplies à volume constant et leurs trousses
CA2901410C (fr) 2013-03-13 2023-09-12 Bruce Chandler May Utilisation de levocetirizine et montelukast dans le traitement de blessure traumatique
MX2015011905A (es) 2013-03-13 2016-01-08 Inflammatory Response Res Inc Uso de levocetirizina y montelukast en el tratamiento de la vasculitis.
ES2745041T3 (es) 2013-03-13 2020-02-27 Inflammatory Response Res Inc Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunitarios
JP2017526728A (ja) 2014-09-15 2017-09-14 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2512796B2 (ja) * 1987-06-24 1996-07-03 オートイミュン・インコーポレイテッド 自己抗原の経口投与による自己免疫疾患の治療法
US5571499A (en) * 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US5571500A (en) * 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases through administration by inhalation of autoantigens
EP0503055A1 (fr) * 1990-09-06 1992-09-16 Rijksuniversiteit Utrecht Inhibiteurs de la reponse de lymphocytes et de maladies immunitaires
DK0627933T3 (da) * 1992-02-28 2003-03-24 Autoimmune Inc Bystander-suppression af autoimmune sygdomme
WO1996040235A1 (fr) * 1995-06-07 1996-12-19 Nexstar Pharmaceuticals, Inc. Procede d'utilisation de superantigenes pour cibler des sous-populations de lymphocytes t
WO1996041644A1 (fr) * 1995-06-13 1996-12-27 Nippon Meat Packers, Inc. Medicament a administration par voie orale, contre la polyarthrite rhumatoide et aliment actif

Also Published As

Publication number Publication date
NO993600L (no) 1999-09-23
WO1998032451A1 (fr) 1998-07-30
HUP0001960A2 (hu) 2000-10-28
CA2278152A1 (fr) 1998-07-30
AU6648898A (en) 1998-08-18
BR9807112A (pt) 2001-09-18
EP0994717A1 (fr) 2000-04-26
JP2001511134A (ja) 2001-08-07
KR20000070460A (ko) 2000-11-25
EP0994717A4 (fr) 2000-07-26
NO993600D0 (no) 1999-07-23

Similar Documents

Publication Publication Date Title
IL131025A0 (en) Treatment of autoimmune disease using tolerization in combination with methotrexate
ZA989461B (en) Methods and compositions for the treatment of autoimmune disease using heat shock proteins
ZA9710339B (en) Xanthines and their therapeutic use
HUP0004439A3 (en) 1-substituted-1-aminomethyl-cycloalkane derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
ZA983452B (en) Substituted pyrrolopyridines useful in the treatment of inflammatory diseases.
EP0924983A4 (fr) S(-)-tolterodine pour le traitement des troubles urinaires et gastro-intestinaux
EP0966386A4 (fr) Vehicule a traction humaine
IL139589A0 (en) Use of cyclosporins in the treatment of inflammatory autoimmune diseases
HUP0001276A2 (en) Illuminating body for swimming pools and similar
ZA984174B (en) Novel triptolide derivatives useful in the treatment of autoimmune diseases
HU9602750D0 (en) Treatment of autoimmune disease using oral tolerization and/or type i interferon
HU9602751D0 (en) Treatment of autoimmune disease using oral tolerization and/or th2-enhancing cytokines
HUP9900147A3 (en) Therapeutic agents and autoimmune diseases
GB9419553D0 (en) Polypeptides and their use in the treatment of auto-immune disease
HK1025954A1 (en) Triptolide derivatives useful in the treatment of autoimmune diseases
EP0797440A4 (fr) Traitement de maladies auto-immunes au moyen de derives de 2-amino purine
AU2976597A (en) Autoimmune disease therapeutic agent
GB9621825D0 (en) Microparticles and their use as therapeutic vehicles
GB9705200D0 (en) Well treatment with particles
IL129460A0 (en) Use of lofexidine in the treatment of behavioral disorders
EP1073459A4 (fr) Compositions et methodes visant a induire une tolerance dans l'evolution d'une maladie a mediation assuree par un complexe antigene-anticorps
HUP9902802A3 (en) Pyridyl- and pyrimidyl-piperazines in the treatment of substance abuse disorders
AU7262800A (en) Diagnostic and therapeutic methods in autoimmune disease
EP1020517A4 (fr) Gene issu de chondrocyte humain
IL132845A0 (en) Non-myeloablative tolerogenic treatment